Scribe Therapeutics, Inc. (SCTX) — Dilution Risk Analysis
Current Snapshot
Scribe Therapeutics, Inc. (SCTX) has a DilutionWatch score of 48/10 and is classified as MEDIUM risk. The score date in the source data is 2026-10-03T03:45:52.527348.
This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.
Dilution Risk Score
Score: 48/10 Source (as of 2026-10-03T03:45:52.527348)
Recent SEC Filings
Recent filing forms in the source payload: 8-K 1, 3 3, EFFECT 1.
| Form | Filed | Accession |
|---|---|---|
| 8-K | 2026-07-27 | 0001193125-26-318263 |
| 3 | 2026-07-23 | 0001231919-26-000795 |
| 3 | 2026-07-23 | 0000947871-26-000715 |
| 3 | 2026-07-23 | 0001193125-26-314787 |
| EFFECT | 2026-07-23 | 9999999995-26-002417 |
Dilution Risk Drivers
No shelf, ATM, cash-runway, or share-growth risk-driver values were present in the current source payload.
DilutionWatch Analysis
- Risk Level
- MEDIUM (Score: 48/10) Source
What This Page Does Not Estimate
DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.
Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.